Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications [Yahoo! Finance]
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $62.00 price target on the stock.
Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results [Yahoo! Finance]
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.